Description
Sibutramine 15 mg PharmaGroup — sibutramine from PharmaGroup at 15 mg. SNRI appetite suppressant. Withdrawn from EU/US markets on cardiovascular risk; still dispensed in some jurisdictions.
Key Benefits
- Serotonin-norepinephrine reuptake inhibitor — centrally-acting appetite suppressor
- Metabolic rate elevation modest; mechanism primarily satiety
- Withdrawn from many markets due to cardiovascular signal
- Oral daily dosing during cutting
- Not first-line in modern weight-loss protocols (GLP-1 agonists preferred)
- Each unit dosed at 15 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Clinical dosing (historical): 10–15 mg/day, single morning dose. Cycles 8–12 weeks with careful BP and heart-rate monitoring. Modern protocols largely replace sibutramine with GLP-1 agonists.
How It Works
Central serotonin and norepinephrine reuptake inhibitor (SNRI). Increases satiety signals and modestly raises basal metabolic rate. Withdrawn from EU, US, and most developed markets in 2010 after cardiovascular-event signal in SCOUT trial.
Pharmacokinetics
Plasma half-life approximately 14–16 hours (active metabolites longer). Daily morning dosing. Steady-state 4–5 days.
Potential Side Effects
Blood-pressure elevation, tachycardia, dry mouth, insomnia. Cardiovascular events in susceptible individuals — primary reason for market withdrawal. Not for hypertensive or CVD patients.
Cycle & Stacking Guide
8–12 week cutting protocols with weekly BP monitoring. Modern alternative: semaglutide or tirzepatide with far cleaner safety profile.
Manufacturer Notes
PharmaGroup is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.